All G: Pioneering Infant Formula Innovation in Sydney

Sydney-based All G is on a mission to redefine infant nutrition. The startup claims to be developing infant formula that is significantly closer to the nutritional gold standard of human milk, utilizing groundbreaking technology that forms human casein proteins into micelles—critical building blocks for the nutritional and functional benefits of breastmilk.

A Path to Market

All G plans to debut bovine lactoferrin later this year and human lactoferrin in early 2026. The company has recently filed a patent application for a formulation that includes five essential human breast milk proteins, produced through precision fermentation: alpha-lactalbumin, lactoferrin, beta-casein, kappa-casein, and serum albumin. CEO Jan Pacas mentioned that the startup is in discussions with “multiple global infant formula companies” aiming to create products that closely mimic human breast milk.

“This is the closest infant formula has ever come to the real thing,” Pacas remarked. The entrepreneur previously co-founded Australia’s largest online pet care marketplace, Mad Paws, and HR software startup Flare, which was sold to MYOB in 2022 before establishing All G in late 2020.

The Science Behind the Innovation

Joining Pacas in 2021, Dr. Jared Raynes brings a wealth of expertise as a molecular biologist who has been engaged in producing phosphorylated beta-casein proteins through microbial fermentation trends since his tenure at Australia’s national agency, CSIRO.

Understanding Human Casein Micelles

Dr. Raynes explained to AgFunderNews that “no one else has been able to manufacture human casein micelles.” Unlike most infant formulas that rely on bovine casein micelles—larger, firmer structures that slow digestion—human caseins are smaller, softer, and better suited for steady nutrient delivery and efficient absorption, which align with infant digestive needs.

“Without the micelle, which is crucial for calcium, phosphate, and other bioactive components delivery, the nutritional value of casein proteins is limited,” he emphasized.

Global Interest in Innovative Formulas

Current infant formulas mostly consist of a carbohydrate base, proteins (often derived from cow’s milk or soy protein isolate), vegetable oils, vitamins, and minerals. Many premium products are further supplemented with nutrients like synbiotics, lactoferrin, alpha-lactalbumin, MFGM, and OPOs.

In the past few years, several manufacturers have begun incorporating human milk oligosaccharides (HMOs) such as 2’FL and LNnT produced through precision fermentation. Although some startups have attempted to create rarer HMOs and essential nutrients from breast milk, human casein micelles have not yet been produced at scale.

Raynes noted, “This achievement offers a pathway to bring infant formula dramatically closer to the nutritional gold standard of human milk.” The company aims to make a significant impact on global infant nutrition through partnerships with other companies.

Path Forward: Manufacturing and Scalability

Regarding scalability, Dr. Raynes stated that their strains are “already cost-effective” for both human lactoferrin and human caseins. They have established commercial partnerships covering major Asian markets, Europe, and the U.S. The company anticipates operating commercial scale bioreactors by Q4 of this year.

Moreover, they’ve already secured self-GRAS status for bovine lactoferrin in the U.S. and will be submitting to the FDA for human proteins soon. “The landscape for approvals for human proteins is more complicated, but we are confident we have an approach that aligns with our launch and scale-up plan,” he added.

All G aims to produce lactoferrin in fermentation tanks using genetically engineered microbes, enabling access to previously limited markets. “We’ve had conversations with big players who indicated that if we can offer a competitive price, they would start incorporating it into yogurts and other mainstream applications,” concluded Raynes.